Drug Interaction Study Between Dorzagliatin and Empagliflozin

Phase 1 Completed 16 enrolled Hua Medicine Limited

NaSequentialOpen-labelTreatment

Summary

This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and empagliflozin in subjects with T2DM. Pharmacokinetics and pharmacodynamics when dorzagliatin and empagliflozin given alone and in combination will be studied.

Timeline

Start: 2019-04-18
Primary completion: 2020-03-15
Completion: 2020-03-15

Publications

Liu H, Zhang Y, Feng L, Zhang J, Sun Y, Zhao Y, Jiang M, Liu X, Tracey GJ, Chen L, Liu D. A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial. Nat Commun. 2026 Apr 21. doi: 10.1038/s41467-026-71798-x. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dorzagliatin	Small molecule	75 mg	—
Subject	Empagliflozin	Small molecule	25 mg	Oral

Indications

No indication recorded.